CEA and CA19.9 as Early Predictors of Progression in Advanced/Metastatic Colorectal Cancer Patients Receiving Oxaliplatin-Based Chemotherapy and Bevacizumab

被引：35
|
作者：
Petrioli, Roberto [1 ]
Licchetta, Antonella [1 ]
Roviello, Giandomenico [1 ]
Pascucci, Alessandra [1 ]
Francini, Edoardo [1 ]
Bargagli, Gianluca [1 ]
Conca, Raffaele [1 ]
Miano, Salvatora Tindara [1 ]
Marzocca, Giuseppe [2 ]
Francini, Guido [1 ]
机构：
[1] Univ Siena, Med Oncol Unit, I-53100 Siena, Italy
[2] Univ Siena, Dept Gen Surg, I-53100 Siena, Italy
来源：
CANCER INVESTIGATION | 2012年 / 30卷 / 01期
关键词：
Capecitabine; CEA; CA19.9; Colorectal cancer; Bevacizumab; Oxaliplatin; Tumor markers; CAPECITABINE PLUS OXALIPLATIN; PHASE-II TRIAL; CARCINOEMBRYONIC ANTIGEN; 1ST-LINE THERAPY; TUMOR-MARKERS; ADENOCARCINOMA; MULTICENTER; SURVIVAL; FOLFOX-4; STAGE;
D O I：
10.3109/07357907.2011.629380
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
We evaluated the changes of the tumor markers CEA and CA19.9 as early predictors of progression in metastatic colorectal cancer (mCRC) patients participating in a clinical study and receiving chemotherapy and bevacizumab (Bev). Seventy-two patients had high baseline CEA or CA19.9 serum levels. By ROC analyses, the areas under the curves were 0.83 for variable CEA cutoff values for distinguishing progressive disease (PD) versus stable disease (SD)/partial remission (PR)/complete remission (CR), and 0.80 for variable CA19.9 cutoff values for distinguishing PD versus SD/PR/CR. Rises in CEA and CA19.9 may early signal the occurrence of progression in mCRC patients receiving chemotherapy and Bev.
引用
收藏
页码：65 / 71
页数：7
相关论文
共 50 条
  • [1] Bevacizumab and oxaliplatin-based chemotherapy in metastatic colorectal cancer
    Beatty, Gregory L.
    Giantonio, Bruce J.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (05) : 683 - 688
  • [2] Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients
    Formica, V.
    Massara, M. C.
    Portarena, I.
    Fiaschetti, V.
    Grenga, I.
    Blanco, G. Del Vecchio
    Sileri, P.
    Tosetto, L.
    Skoulidis, F.
    Pallone, F.
    Roselli, M.
    CANCER BIOMARKERS, 2009, 5 (4-5) : 167 - 175
  • [3] Treatment of advanced and/or metastatic colorectal cancer with bevacizumab in combination with oxaliplatin-based chemotherapy (Folfox7 regimen)
    Oukkal, M.
    Djilat, K.
    Hadjam, R. M.
    Mahgoun, M. T.
    Bentabak, K.
    Graba, A.
    Smail, N.
    Kaci, N. Ait
    Ahmed, R. Baba
    Bouzid, K.
    BULLETIN DU CANCER, 2010, 97 (04) : 469 - 474
  • [4] A Post Hoc Analysis of Older Patients with Metastatic Colorectal Cancer Receiving Oxaliplatin-Based Chemotherapy Plus Bevacizumab: The Randomized Obelics Study
    Rosati, Gerardo
    Piccirillo, Maria Carmela
    Nasti, Guglielmo
    De Stefano, Alfonso
    Carlomagno, Chiara
    Romano, Carmela
    Cassata, Antonino
    Silvestro, Lucrezia
    Nappi, Anna
    Perrone, Franco
    Budillon, Alfredo
    Avallone, Antonio
    DRUGS & AGING, 2025, : 353 - 362
  • [5] MIR-133A IS A PREDICTIVE BIOMARKER IN PATIENTS WITH METASTATIC COLORECTAL CANCER RECEIVING OXALIPLATIN-BASED CHEMOTHERAPY
    Ng, Simon S.
    Dong, Yujuan
    Leung, Wing Wa
    Ma, Brigette B.
    To, Ka Fai
    Sung, Joseph J.
    Yu, Jun
    GASTROENTEROLOGY, 2018, 154 (06) : S88 - S88
  • [6] Comparison between three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer
    Ohhara, Yoshihito
    Suenaga, Mitsukuni
    Matsusaka, Satoshi
    Shinozaki, Eiji
    Mizunuma, Nobuyuki
    Yamaguchi, Toshiharu
    ONCOTARGETS AND THERAPY, 2015, 8 : 529 - 537
  • [7] Oxaliplatin-based chemotherapy in the treatment of elderly patients with metastatic colorectal cancer (CRC)
    Berretta, Massimiliano
    Zanet, Ernesto
    Nasti, Guglielmo
    Lleshi, Arben
    Frustaci, Sergio
    Fiorica, Francesco
    Bearz, Alessandra
    Talamini, Renato
    Lestuzzi, Chiara
    Lazzarini, Renzo
    Fisichella, Rossella
    Cannizzaro, Renato
    Iaffaioli, Rosario Vincenzo
    Berretta, Salvatore
    Tirelli, Umberto
    ARCHIVES OF GERONTOLOGY AND GERIATRICS, 2012, 55 (02) : 271 - 275
  • [8] CEA, CA19.9, IL-6, AND SELECTED INFLAMMATORY PARAMETERS IN PATIENTS WITH COLORECTAL CANCER
    Stasik, Z.
    Wysocki, W.
    Wojcik, E.
    Tarapacz, J.
    Rychlik, U.
    Kulpa, J. K.
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2011, 49 : S273 - S273
  • [9] CA19-9 level as a prognostic and predictive factor of bevacizumab efficacy in metastatic colorectal cancer patients undergoing oxaliplatin-based chemotherapy
    Narita, Yukiya
    Taniguchi, Hiroya
    Komori, Azusa
    Nitta, Sohei
    Yamaguchi, Kazuhisa
    Kondo, Chihiro
    Nomura, Motoo
    Kadowaki, Shigenori
    Takahari, Daisuke
    Ura, Takashi
    Andoh, Masashi
    Muro, Kei
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (02) : 409 - 416
  • [10] CA19-9 level as a prognostic and predictive factor of bevacizumab efficacy in metastatic colorectal cancer patients undergoing oxaliplatin-based chemotherapy
    Yukiya Narita
    Hiroya Taniguchi
    Azusa Komori
    Sohei Nitta
    Kazuhisa Yamaguchi
    Chihiro Kondo
    Motoo Nomura
    Shigenori Kadowaki
    Daisuke Takahari
    Takashi Ura
    Masashi Andoh
    Kei Muro
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 409 - 416
12345